World
Russia’s Vaccine Matters to the World
By Kester Kenn Klomegah
President Vladimir Putin has praised the entire healthcare system and particularly the hard-working team of scientists and specialists from different institutions for their efforts at research and creating a series of coronavirus vaccines for use against the coronavirus both at home and abroad.
Three vaccines already registered in Russia, two of them – Sputnik V and EpiVacCorona – are produced in large quantities by Russian pharmaceutical companies and are currently used for vaccination. It is additionally planned to roll out another one – CoviVac.
Despite the pandemic-related challenges, the domestic pharmaceutical companies, in conjunction with research institutes, have managed to accomplish a multitude of objectives in order to deploy new vaccine production sites in a short amount of time, Putin said during a videoconference meeting focused on increasing the manufacturing capacity of COVID-19 vaccines and the progress of vaccination in Russia.
Unreservedly made reference to staff qualities such as consistent and effective hard-work, truly selfless work and responsible attitude, and further urged them to continue making relentless efforts in stabilising the spread of the coronavirus infections and in protecting the life and health of millions of people in the country.
Putin further noted that the implementation of a wide range of preventive measures, including widespread vaccination, has played a significant role in normalising the epidemic situation.
Overall, 6.3 million Russians have taken the first part of the vaccine, of these 4.3 million have been vaccinated in full, that is, they have received both vaccine components.
“We can safely say, and the practical results indisputably corroborate, the fact that the Russian vaccines are absolutely safe and dependable. Our success is recognised abroad as well. The number of countries using the Sputnik V vaccine is expanding fast, more countries around the world are showing interest in our vaccine with 55 countries having authorised its use,” he told the meeting.
In addition, Russia now has a number of contracts with foreign manufacturers, – these are foreign manufacturers who will be producing our vaccine on their territory – have been signed for the number of doses needed to vaccinate 700 million people per year.
The latest, it has signed a contract with an Indian company for doses to vaccinate 100 million people. Indisputably, working with 55 countries means a total population of 1.4 billion. There are plans to expand the number of partner countries and that will reach an estimated 2.5 billion people.
While Russia and its pharmaceutical companies are considering the dynamics of the global market and the demand for Russian-made vaccines, and expanding their production capacities, it equally places emphasis on domestic needs, supplying and vaccinating Russian citizens with vaccines, is an absolute priority.
It is estimated that at least 60 per cent of all adults in the country must be vaccinated for complete stabilisation. This requires 69.8 million sets of vaccine doses. At any rate, there are more than 20 million Sputnik V doses, according to the Russian president, quoting his Prime Minister Mikhail Mishustin.
In his contribution at the meeting, Minister of Industry Denis Manturov informed that under the plan, 12.5 million sets of the vaccine must be produced in March. The planned figure for April is 17 million. It is planned to continue building up production so as to have over 80 million two-component doses by the first six months.
According to him, all these amounts will be primarily used to vaccinate Russian citizens. In order to meet the global demand for Russian vaccines, his ministry is working on scaling up the production of vaccines and on transferring technology abroad. It already has comprehensive agreements on this with manufacturers in 10 countries.
Healthcare Minister Mikhail Murashko informed the meeting about organisations that keep monitoring the virus’s mutations, including those in Russia. “We are analysing the efficiency of medicines for preventing the disease caused by various strains. This work is ongoing continuously and involves several agencies,” he said, and further mentioned the need to increase the speed of vaccination.
By the end of March, our healthcare facilities will receive over 6.5 million doses of Sputnik V. We expect that a total of some 30 million doses will be delivered in April and May. As of now, there are 4,500 stationary vaccination stations across Russia and plans to increase this figure, as well as over 1,000 mobile stations.
Participating in the meeting, Pharmstandard Chairman of the Board Viktor Kharitonin also discussed the production capability of the vaccine and pointed to the successful completion of the transfer of laboratory technology, scaled and fine-tuned the manufacturing technology abroad.
“It should be specifically pointed out that, thanks to our cooperation with the Russian Direct Investment Fund, we have started supplying the vaccine to foreign markets. We have already transferred the production technology to Kazakhstan and Belarus and continue working with other countries, including India and Italy. In Italy, Sputnik V was highly praised by both scientists and our colleagues from pharmaceutical companies,” added Kharitonin.
Taking his turn, Chairman of the Board of the R-Pharm Group Alexei Repik talked about efforts that are currently focused on the creation and manufacturing of new forms of the vaccine that will be easier to use and also to transport. He noted that it will increase the attractiveness of the vaccines on foreign markets, including countries with a hot climate: the Middle East, Africa and Latin America.
“Our factory is now producing the first registration batches of a promising lyophilic form of the vaccine created by our experts. It has proved stable at temperatures between +2 and +8 C. We are now studying its stability at room temperature. There are grounds to believe that we will succeed. This form will allow us to make the vaccine available in hard-to-reach regions of the country, which is especially important ahead of the spring and summer period,” informed Alexei Repik.
Director of the Gamaleya National Research Centre for Epidemiology and Microbiology Alexander Gintsburg also highlighted a few aspects of the vaccine production and about documents for registration. According to him, the Gamaleya Research Centre also addresses the problem of expanding the production of the Sputnik Light vaccine.
In addition, as the holder of the registration certificate, the Centre assumes all responsibility for quality control of this vaccine at all enterprises where it is manufactured in this country and abroad.
Moreover, the Centre is directly involved in launching contractual production that is mostly organised by the Russian Direct Investment Fund. The Centre has prepared the entire package of documents for registering the Sputnik Light vaccine in 55 countries. Considering that each country has its own regulatory system, this is not a fixed package of documents that will apply everywhere, therefore it has to adapt it to every country’s regulatory system.
He further spoke about The Lancet, a highly prestigious and popular medical journal, that published two articles on the results of scientific data and clinical trials. This provides important scientific evidence proving the vaccine’s efficacy, this has completely eliminated the Western academic community’ scepticism regarding the vaccines’ quality and efficacy.
Alexander Gintsburg explained a little about children’s vaccination. According to him, children must be divided into several age groups. Russian experts and specialists in paediatric immunology are working in this direction. He said that a vaccine has been developed, patented, and are currently launching clinical trials of Sputnik V’s intranasal form. This is a very gentle and patient-friendly form of vaccination for children, especially little children, who can be traumatised when they see a syringe or when possible side effects arise. The first experiments show that the intranasal form is completely free from any side effects.
CEO of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev stressed patent protection and protecting intellectual rights for Russian made vaccines and other medical products. “Our patent protection is very strong. We submitted applications early on, much earlier than other countries, and thus got a headstart. Accordingly, the Gamaleya Institute owns the innovations that are available even at these foreign sites, which include over 20 partner companies in 10 countries,” he told the meeting.
On foreign cooperation, “Mr President, I would like to thank you, because it was your idea to build production partnerships with various countries, and 20 manufacturers from over 10 countries responded. For them, it’s about vaccine safety and independence, and Russia was the only country to have come up with this offer. Thank you very much. They are very grateful to you for this,” Kirill Dmitriev said in appreciation.
Director-General of the Vektor State Research Centre of Virology and Biotechnology Rinat Maksyutov discussed various research operations. Vektor is the only WHO COVID-19 reference laboratory in Russia. It not only conducts the entire range of viral studies of the novel coronavirus but is also monitoring its genetic mutations across the country on a regular basis.
“By now, we have found over 5,300 genetic variations across the genome. In the overwhelming number of cases, the replacement does not change the epidemiological characteristics of the virus. At the same time, we have also found over 50 variations of the British strain, three cases of the South African strain and over 20 unique variations of the virus that must be thoroughly studied,” he said.
According to Rinat Maksyutov, the Research Centre Vektor is studying these variations of the virus in accordance with a special algorithm. “We are studying the virus’s stability on various surfaces; we are also using unique equipment, which has no analogues throughout the world, to study the ability of the virus to be transmitted between living organisms. We have found that the British strain of the novel coronavirus can be effectively neutralised by serum taken from those who had COVID and those vaccinated with Sputnik V or EpiVacCorona,” he told the meeting.
Director-General of the Chumakov Federal Scientific Centre for the Research and Development of Immune and Biological Products (Russian Academy of Sciences) Aidar Ishmukhametov spoke about their engagement and involvement in research and production of medical products, tracing its roots to the Soviet Union.
The Chumakov Centre is one of the oldest facilities in the Russian Federation and the oldest vaccine developer in Russia. That in the 1960s, this centre’s achievements helped the country deal with polio. The centre back then developed a unique vaccine that supplied to the entire world, including the United States, Europe, Japan and many other countries. In fact, now this facility, the Institute of Poliomyelitis, is well-known around the world.
It is continuing this tradition. As of today, it has developed and produced five vaccines, including for tick-borne encephalitis, rabies and the yellow fever vaccine that is supplied to almost 50 countries, which is perhaps Russia’s biggest export in the pharmaceutical industry.
This type of organisation that has a research and development facility at its core that can outline the task and release a certain number of batches of the vaccine consisting of tens of millions [of doses], on one hand, and well-coordinated work with research institutes and the search for partners, on the other hand, is a very efficient model.
“We did not intend to work exclusively on the coronavirus vaccine. It was important to us to maintain the same production volume and supply vaccines according to the national vaccination calendar as well as deliver on the exports. So we needed to fit this new objective into our existing model. We inherited this research and development facility from the Soviet Union where it was a leader in this industry, and we are developing it,” he underlined the importance of his institution at the meeting.
CEO of the National Immunobiological Company, Rostec State Corporation, Andrei Zagorsky, however, noted that vaccine production is growing steadily. He highlighted the question of warehousing (storage), freezer facility and shipping to the regions. This is carried out in close cooperation with the manufacturing sites, as well as cargo recipients in the regions. These tasks are fulfilled on schedule, he said.
“We monitor the entire production process, especially the temperature, all the way from production, transport, acceptance to a warehouse, storage at the warehouse, to shipment to a recipient region. All products are transported in thermal containers, which can keep temperatures at 18 degrees below zero Celsius for about five days,” he added, speaking at the meeting.
Deputy Prime Minister Tatyana Golikova concluded with high appreciation. The meeting ended with a clear understanding of what direction should be moving to overcome the coronavirus pandemic and at the same time, extend assistance to foreign countries that are in need.
She, however, reiterated that, in a fairly short time, despite the difficulties and amid the challenging pandemic of 2020, all her colleagues have indeed accomplished something that seemed almost impossible, worked 24/7 and made Russia the leader in the production and use of vaccines, primarily, for the public in Russia.
Kester Kenn Klomegah is a versatile researcher and a passionate contributor. Most of his well-resourced articles are reprinted elsewhere in a number of reputable foreign media.
World
Essent Slashes Contact Centre Technology Costs by 50%
By Modupe Gbadeyanka
The Netherlands’ largest energy provider, Essent, has cut the technology costs of its contact centre infrastructure by half.
The organisation, which serves 2.5 million customers, recorded zero critical incidents post-migration and improved agent workplace satisfaction by 36 per cent.
The migration was delivered in partnership with AI-first customer experience transformation specialists, Sabio Group, and was completed in under 12 weeks for an operation spanning over 1,000 agents across two locations.
Agents were forced to juggle multiple disconnected screens simultaneously — a workflow that was as inefficient as it was stressful.
“Our agents were constantly working with different screens — multiple chat instances open at once, multiple agent desktop instances. It was messy, and in some cases, quite stressful,” SAFe Product Manager for Customer Interaction, Omnichannel and Digital Transformation at Essent, Michiel Kouijzer, stated.
“A lot of colleagues were saying I was mad for even suggesting this approach. It kind of feels like a victory on a personal level that it did work out. You just have to be a little ambitious — and have the right expert partner who can make it work,” Kouijzer added.
With stable cloud infrastructure now firmly in place, Essent is turning its attention to the capabilities that were impossible in its legacy environment: AI-powered call summarisation, agentic customer self-service, and next-generation workforce optimisation.
Rather than a reckless ‘big bang’ cutover that could have affected service to millions of households, Sabio engineered a phased migration strategy — beginning with Essent’s SME segment to validate technical readiness before scaling to the full enterprise operation.
“This project showcases Sabio’s unique position in the contact centre technology landscape. We’re not just moving Essent to the cloud — we’re establishing a foundation for continuous improvement in their customer experience delivery,” the Country Manager for Sabio Group Benelux, Wouter Bakker, commented.
World
Africa: A New Market for Russian Business
By Kestér Kenn Klomegâh
On April 11, the presentation of the book “Africa: a new market for Russian business” took place, which aroused lively diverse interests among business representatives, entrepreneurs and employees of federal structures of Russia. The event was dedicated to discussing the prospects of Russian companies entering the African market and became a platform for the exchange of views and experiences.
Participating guests, packed in the small hall, included:
– representatives of business circles,
– entrepreneurs interested in new directions of development,
– employees of federal agencies curating foreign economic activity.
The presentation was held in a constructive and friendly atmosphere. The author of the book, Serge Fokas Odunlami, detailed the key ideas and conclusions presented in the publication. Particular attention was paid to the practical aspects of operating in the African market, as well as the analysis of opportunities and risks for Russian companies.
During the lively discussion, participants asked questions, shared their experiences and made suggestions for developing cooperation with African countries. This format allowed not only to get acquainted with the content of the book, but also to discuss topical issues of expanding business relations.
Meaning of the book: The publication, “Africa: a new market for Russian business” offers readers not only analytical, but also practical recommendations on investment and market trends, and how to enter the African market. The book will be a useful tool for those considering Africa as a promising destination for investment and business development.
The presentation of the book became a significant event for the Russian business community interested in expanding cooperation with Africa. Serge Fokas Odunlami introduced the participants to the new edition, which is a comprehensive business guide that gives an impetus for dialogue and implementation of joint entrepreneurial projects and corporate initiatives across Africa.
World
Ryan Collyer Reveals Reasons Behind Africa’s Significant Energy Deficit
By Kestér Kenn Klomegâh
Perhaps Russia’s state nuclear corporation, Rosatom, is at the frontline, shaping Africa’s energy security. And African countries are also accelerating coordinated efforts to build nuclear power plants primarily to supply their energy, which will drive industrialisation and boost power capacity for domestic utilisation.
Energy experts say adopting nuclear can further support a diverse energy mix, reduce reliance on fossil fuels, and help across the continent. Over the past two decades, Russia has been collaborating with African countries, adopting energy initiatives to provide power to approximately half the continent’s population, and making it an important component of Africa’s future energy strategy and solutions. At this point, however, it is necessary to underline the irreversible fact that Russia’s ultimate goal is to ensure long-term African energy security.
In this interview, Rosatom’s Chief Executive Director for Central and Southern Africa, Ryan Collyer, reiterates the strategic importance of Russia-Africa’s energy cooperation through strengthening bilateral agreements on collaboration on the peaceful use of nuclear energy. Collyer explains that the Russian approach is its ability to offer an integrated solution, from technology and financing to training and localisation. According to him, partnerships must be built on mutual benefit and on the principle of transparency. Here follows the interview excerpts:
What are the expectations, specifically in the nuclear energy sphere, for Africa during the forthcoming Russia–Africa Summit scheduled for 2026?
The expectation is a clear shift from dialogue to delivery. Over the past few years, we have built a strong foundation through agreements, feasibility discussions and partnerships. The 2026 Russia–Africa Summit is an opportunity to demonstrate tangible progress.
In practical terms, I would expect greater focus on implementation readiness. That includes regulatory development, human capital, financing models and localisation strategies. We also expect to see more structured cooperation in areas like small modular reactors, which are particularly relevant for many African grids, as well as stronger emphasis on education and training partnerships. Ultimately, the success of the Summit will be measured by how many initiatives move from concept to execution.
Why, despite many bilateral agreements, is Africa still experiencing a significant energy deficit?
Africa’s energy deficit is not a result of a lack of ambition or agreements. It is primarily a question of scale, financing and infrastructure readiness. Energy projects, especially large-scale ones, require long-term investment, stable policy frameworks and strong institutional capacity. Many countries are working under fiscal constraints, and at the same time, demand is growing rapidly due to population growth and urbanisation. So, even when progress is made, it can be outpaced by rising demand.
It is also important to understand that many agreements are not meant to deliver immediate infrastructure. They are part of a longer preparation cycle, including feasibility studies, regulatory development and workforce training. Nuclear projects in particular are long-term by nature, and while this can be perceived as slow progress, it is actually a reflection of the level of diligence required.
How do you assess the contribution of nuclear energy to climate change mitigation and technological development in Africa?
Nuclear energy plays a dual role in Africa’s development, both as a clean energy source and as a driver of technological advancement. From a climate perspective, nuclear provides reliable, low-carbon electricity at scale. Africa needs a significant expansion of its energy capacity to support economic growth, and this growth must be both stable and sustainable.
Nuclear allows countries to increase power generation without increasing emissions, while ensuring a consistent baseload supply. At the same time, its impact goes beyond electricity. Nuclear technologies support medicine, agriculture, water management and industrial processes. Across Africa, they are already used in areas such as cancer treatment, food preservation and environmental monitoring, making nuclear a broader platform for sustainable development.
In this context, Rosatom offers integrated solutions across the full nuclear value chain. This includes large-scale and small modular reactors, as well as advanced non-power applications such as nuclear medicine and irradiation technologies. Our focus is on delivering practical, tailored solutions that support long-term development and local capacity building.
Is Africa unprepared to deal with nuclear waste, as some critics suggest?
I would say that preparedness varies across countries, but it would be inaccurate to suggest that the issue is being ignored. Responsible nuclear programmes require a comprehensive approach to waste management from the very beginning. This includes legal frameworks, regulatory oversight, storage solutions and long-term planning. These elements are part of international best practice and are supported by organisations such as the IAEA. What is true is that this topic is often undercommunicated in the public space. It should be discussed more openly, because transparency builds trust.
Countries that are serious about nuclear energy understand that waste management is not optional. It is a core component of the programme, and it is addressed in parallel with all other aspects of development. Rosatom offers comprehensive solutions for spent fuel and radioactive waste management. These include technologies for safe storage, transportation, reprocessing and recycling of nuclear materials. In fact, advanced reprocessing solutions allow for the reuse of valuable components of spent fuel, significantly reducing the volume of waste and improving the overall sustainability of the nuclear cycle.
Nuclear power remains controversial. Why do you believe it is important for Africa, and what role does it play in the energy mix?
Africa needs a balanced and pragmatic energy strategy. The conversation should not be about choosing one technology over another, but about building an energy mix that is reliable, affordable and sustainable. Renewables will play a critical role and are already expanding rapidly. However, they are variable by nature. For industrialisation, countries also need stable, continuous power that is baseload. This is where nuclear can make a meaningful contribution. A diversified energy mix that includes renewables, nuclear, hydropower and other sources allows countries to reduce risk, improve energy security and support long-term economic growth.
Nuclear is not the only solution, but it is an important part of a resilient system, especially for countries with growing industrial ambitions. In this context, Rosatom is able to support countries with integrated energy solutions that combine reliability, sustainability and long-term partnership models, tailored to national development priorities.
How can we shift public perception, given the legacy of Chornobyl and Fukushima?
We cannot rewrite history, and we should not try to. Events like Chornobyl and Fukushima shaped public perception for a reason. The starting point is respect for those concerns, not dismissal. At the same time, what is often missing in the conversation is what happened after those events. Chornobyl, in particular, fundamentally reshaped the entire philosophy of nuclear safety. It led to a complete rethinking of reactor design, emergency response, and regulatory oversight. Independent regulators were strengthened, safety responsibilities were clearly separated from operators, and safety culture became not just a principle but a legal requirement supported by continuous drills and probabilistic risk assessments.
Technologically, the industry also changed dramatically. Modern reactors are designed to withstand even worst-case scenarios, with multi-layered “defence-in-depth” systems, core melt traps, and passive safety mechanisms that rely on natural physical processes rather than human intervention. These are not incremental improvements. They are the direct result of lessons learned at a very high cost. But facts alone do not change perception. People do not build trust through reports. They build it through experience and transparency. That is why our approach in Africa is deliberately open.
We create opportunities for students, young professionals and journalists to visit nuclear facilities, research centres and training programmes. When people can see how systems operate, how safety is managed, and how seriously it is taken, the conversation becomes more grounded and less abstract. There is also an important human dimension that is often overlooked.
The history of Chornobyl is not only a story of tragedy. It is also a story of professionalism, responsibility and the people who managed the crisis and generated the knowledge that made today’s safety standards possible. Acknowledging that the full picture helps move the discussion away from fear alone toward understanding. At the same time, we need to broaden the narrative. Nuclear is not only about power generation. It is about cancer treatment, food security, water management and high-skilled employment. When communities begin to connect nuclear technology with real benefits in their own lives, it stops being an abstract risk and starts becoming a practical solution. Ultimately, perception does not change through persuasion. It changes through consistency. Through transparency, long-term engagement, and real-world impact.
What are your final thoughts on Russia’s preparedness to support Africa’s nuclear ambitions?
Russia has demonstrated that it is committed to long-term partnerships in Africa, particularly in the nuclear sector. We are already seeing concrete examples of cooperation in areas such as project development, education and skills transfer. The key strength of the Russian approach is its ability to offer an integrated solution, from technology and financing to training and localisation. Partnerships must be built on mutual benefit and transparency. Africa’s priorities are clear: energy security, economic development and local capacity building. Any partner that is ready to contribute to these goals consistently and practically will have a meaningful role to play. If we look country by country, the picture becomes even more interesting.
Take Ethiopia. This is a country thinking long-term about energy security and industrialisation. It has strong hydropower, but also understands the need to diversify. Ethiopia is prepared to take a big step towards nuclear energy. In Rwanda, the approach is different. It is focused on innovation and speed. There is a strong interest in small and flexible nuclear technologies, alongside active use of nuclear science in healthcare and agriculture. What stands out is the clarity of vision and pace of implementation.
Then, there is Namibia. As a major uranium producer, the question is how to move up the value chain. Partnerships can help connect resources to technology, skills and future energy applications. So, Russia’s role is not one-size-fits-all.
The real strength lies in adapting to each country’s strategy. If that continues, nuclear cooperation becomes not just about energy, but about shaping long-term technological development. Rosatom is one of the few global players capable of delivering the entire nuclear value chain. This includes reactor technologies, fuel supply, waste management solutions, including reprocessing, as well as long-term operational support and human capital development. This comprehensive capability is what allows us to move projects from concept to reality in a structured and sustainable way.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn
